December 13, 2016
Takeda Pharmaceutical’s Entyvio (vedolizumab) showed higher response rates in patients with moderately to severely active Crohn’s disease who received it as a first-line biologic after conventional therapy failure versus those who previously failed on anti-tumor necrosis factor (TNF) therapies, the...read more